{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:13:33Z","timestamp":1748405613563,"version":"3.41.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.1182\/bloodadvances.2024014407","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:09:16Z","timestamp":1739974156000},"page":"2422-2427","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells"],"prefix":"10.1182","volume":"9","author":[{"given":"Sara E. F.","family":"Kost","sequence":"first","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Saleh","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8657-1053","authenticated-orcid":false,"given":"Jennifer","family":"Brown","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shek H.","family":"Yuan","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Kuzio","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-8818","authenticated-orcid":false,"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"3Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"},{"name":"4Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-732X","authenticated-orcid":false,"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"5Department of Oncology, University of Alberta, Edmonton, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-083X","authenticated-orcid":false,"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"3Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-4054","authenticated-orcid":false,"given":"Sachin","family":"Katyal","sequence":"additional","affiliation":[{"name":"1Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"1","key":"2025052708420250700_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"2025052708420250700_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a035220","article-title":"Chronic lymphocytic leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"21","key":"2025052708420250700_bib3","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits B-cell receptor and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with chronic lymphocytic leukemia","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025052708420250700_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3109\/10428194.2013.829919","article-title":"The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia","volume":"55","author":"Stankovic","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025052708420250700_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.23978","article-title":"High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome","volume":"90","author":"Jain","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2025052708420250700_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.2028","article-title":"Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone","volume":"31","author":"Marasca","year":"2013","journal-title":"Hematol Oncol"},{"issue":"4","key":"2025052708420250700_bib7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/leu.2011.281","article-title":"Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage","volume":"26","author":"Britt-Compton","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2025052708420250700_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2019.07.004","article-title":"Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia","volume":"19","author":"Kipps","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025052708420250700_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00781-8","article-title":"DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease","volume":"13","author":"Kost","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025052708420250700_bib10","doi-asserted-by":"crossref","first-page":"111695","DOI":"10.1016\/j.mrfmmm.2020.111695","article-title":"Clinical potential of ATM inhibitors","volume":"821","author":"Lavin","year":"2020","journal-title":"Mutat Res"},{"issue":"4","key":"2025052708420250700_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2025052708420250700_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","article-title":"Beyond DNA repair: DNA-PK function in cancer","volume":"4","author":"Goodwin","year":"2014","journal-title":"Cancer Discov"},{"issue":"12","key":"2025052708420250700_bib13","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1158\/1078-0432.CCR-07-5158","article-title":"DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia","volume":"14","author":"Willmore","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025052708420250700_bib14","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","article-title":"Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)","volume":"120","author":"Yang","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"6","key":"2025052708420250700_bib15","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"issue":"3","key":"2025052708420250700_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/0008-5472.CAN-06-2371","article-title":"Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response","volume":"67","author":"Golding","year":"2007","journal-title":"Cancer Res"},{"issue":"10","key":"2025052708420250700_bib17","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol Cancer Therapeut"},{"issue":"24","key":"2025052708420250700_bib18","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"2025052708420250700_bib19","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1038\/bcj.2016.69","article-title":"ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion","volume":"6","author":"Jiang","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025052708420250700_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/10428194.2016.1204654","article-title":"Modeling the chronic lymphocytic leukemia microenvironment in vitro","volume":"58","author":"Crassini","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2025052708420250700_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/cancers11101519","article-title":"Transcriptional modulation by idelalisib synergizes with bendamustine in chronic lymphocytic leukemia","volume":"11","author":"Kost","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"2025052708420250700_bib22","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3390\/cancers12113178","article-title":"RAD51-mediated DNA homologous recombination is independent of PTEN mutational status","volume":"12","author":"Sinha","year":"2020","journal-title":"Cancers"},{"issue":"21","key":"2025052708420250700_bib23","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1158\/1078-0432.CCR-23-0290","article-title":"ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis","volume":"29","author":"Tew","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2422\/2374406\/blooda_adv-2024-014407-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2422\/2374406\/blooda_adv-2024-014407-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:42:10Z","timestamp":1748349730000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2422\/535643\/ATM-inhibition-decreases-ERK-activation-and-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014407","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,15]]}}}